冠心病患者经皮冠状动脉介入治疗死亡率的性别差异Gender differences in mortality after percutaneous coronary intervention
陈顺华,刘小慧,康俊萍,吕强,刘新民,聂绍平,吴嘉惠,张崟,贾长琪,陈方,吕树铮,顾承雄,黄方炯,马长生,吴学思
摘要(Abstract)：
目的确定经皮冠状动脉介入治疗(PCI)后死亡率是否存在性别差异以及女性是否是影响死亡率的独立预测因素。方法回顾性分析2004年7月1日至2005年9月30日北京安贞医院行单纯PCI治疗的2 493名患者(男性1 860例,女性633例),并进行随访,记录临床特征及随访数据。按照性别分组比较两组之间住院死亡率和总死亡率的差异。结果女性年龄较大,术前合并主要疾病的比例较男性高,而左室射血分数(LVEF)较男性好,既往心肌梗死病史及血运重建史较男性少。女性患者术后住院死亡率约是男性的10倍(女性1.1%,男性0.1%,P<0.001);中位数随访时间555 d,随访率93.4%,女性总死亡率高于男性(5%比2%,P=0.003),总死亡风险是男性的2.6倍(HR2.631,95%CI1.217~5.687,P=0.014)。结论女性PCI术后住院死亡率及总死亡率均高于男性。女性是总死亡率的独立危险因素。
关键词(KeyWords)： 冠状动脉疾病;血管成形术,经腔,经皮冠状动脉;性别因素;死亡率
基金项目(Foundation):
作者(Author): 陈顺华,刘小慧,康俊萍,吕强,刘新民,聂绍平,吴嘉惠,张崟,贾长琪,陈方,吕树铮,顾承雄,黄方炯,马长生,吴学思
参考文献(References)：
- [1]Peterson ED,Lansky AJ,Kramer J,et al.Effect of gender on theoutcomes of contemporary percutaneous coronary intervention.Am J Cardiol,2001,88:359-364.
- [2]Aarins CR,Ling FS,Fischi M,et al.In-hospital mortality amongwomen undergoing contemporary elective percutaneous coronaryintervention:a reexamination of the gender gap.Clin Cardiol,2006,29:254-258.
- [3]Abbott JD,Vlachos HA,Selzer F,et al.Gender-based differencesof percutaneous coronary intervention in the drug-eluting stentera.Catheter Cardiovasc Interv,2006,67:25-31.
- [4]Ellis SG,Roubin GS,King SB,et al.In-hospital cardiac mortal-ity after acute closure after coronary angiop lasty:analysis of riskfactors from8207 procedures.J Am Coll Cardiol,1988,11:211-216.
- [5]Kelsey SF,James M,Ho lubkov AL,et al.Results of percutane-ouse transluminal coronary angiop lasty in women:1985-1986National Heart,Lung,and Blood Institute s coronary angiop lastyregistry.Circulation,1993,87:720-727.
- [6]Alfonso F,Hernandez R,Banuelos C,et al.Initial results andlong-term clinical and angiographic outcome of coronary stentingin women.Am J Cardiol,2000,86:1380-1383.
- [7]Chiu JH,Bhatt DL,Ziada KM,et al.Impact of female sex on out-come after percutaneous coronary intervention.Am Heart J,2004,148:998-1002.
- [8]Abbott JD,Vlachos HA,Selzer F,et al.Gender-based outcomesin percutaneous coronary intervention with drug-eluting stents(from the National Heart,Lung,and Blood Institute DynamicRegistry).Am J Cardiol,2007,99:626-631.
- [9]Tillmanns H,Waas W,Voss R.Gender differences in the outcomeof cardiac intervention.Herz,2005,30:375-389.
- [10]Berger JS,Sanborn TA,Sherman W,et al.Influence of sex on in-hospital outcomes and long-term survival after contemporary per-cutaneous coronary intervention.Am Heart J,2006,151:1026-1031.
- [11]Verhoef P.Hyperhomocysteinemia and risk of vascular disease inwomen.Semin Thromb Hemost,2000,26:325-334.
- [12]Hoogeveen EK,Kostense PJ,Jakobs C,et al.Hyperhomocys-teinemia increases risk of death,especially in Type II diabetes.Five-year follow-up of the Hoorn Study.Circulation,2000,101:1506-1511.
- [13]Johnson BD,Kip KE,Marroquin OC,et al.Serum amyloid A as apredictor of coronary artery disease and cardiovascular outcome inwomen:the National Heart,Lung,and Blood Institute-SponsoredWomen,s Ischemia Syndrome Evaluation(WISE).Circulation,2004,109:726-732.
- [14]von Mering GO,Arant CB,Wessel TR,et al.Abnormal coro-nary vasomotion as a prognostic indicator of cardiovascular eventsin women:results from the National Heart,Lung,and Blood In-stitutesponsored Women s Ischemia Syndrome Evaluation(WISE).Circulation,2004,109:722-725.
- [15]Kannel WB.Risk factors for cardiovascular disease in women.Cardiol Rev,2001,18:11-16.
- [16]Manolio TA,Pearson TA,Wenger NK,et al.Cholesterol andheart disease in older persons and women.Review of an NHLBIworkshop.Ann Epidemiol,1992,2:161-176.
- [17]Wilson PWF,Kannel WB,Silbershatz H,et al.Clustering ofmetabolic factors and coronary heart disease.Arch Intern Med,1999,159:1104-1109.